<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831661</url>
  </required_header>
  <id_info>
    <org_study_id>10-VIN-183</org_study_id>
    <nct_id>NCT01831661</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition</brief_title>
  <official_title>A Randomized, Open Label, Two-treatment, Two -Period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India and GLUCOPHAGE®XR (Metformin HCl Extended-release Tablets) 750 mg of Bristol-Myers Squibb Company, USA in Normal, Healthy, Adult, Human Subjects Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IPCA Laboratories Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IPCA Laboratories Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was a randomized, open label, two-treatment, two-period, two-sequence, single dose,
      crossover, oral bioequivalence study in normal, healthy adult human subjects under fasting
      condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective of the study is to compare and evaluate the single-dose oral bioavailability of
      Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
      and GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb
      Company, USA in normal, healthy, adult, human subjects under fasting condition.

      Total duration of the study was of 17 days from the day of admission of first period till the
      end of second period.

      Upon entering into the study, subjects were housed in clinical facility of Veeda Clinical
      Research Pvt. Ltd. to ensure 10 hours overnight fasting before dosing and continued to be
      housed in the facility till 36.00 hours post-dose blood sample collection in each of the two
      periods.

      A gap of 14 days was kept as wash out between each consecutive dosing period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence is based on Cmax and AUC parameters.</measure>
    <time_frame>1 Months</time_frame>
    <description>Pre-dose &amp; at 1.00, 2.00, 3.00, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 9.00, 10.00, 12.00, 16.00, 20.00, 24.00, 30.00 and 36.00 hours post-dose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>GLUCOPHAGE®XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb Company, USA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin Hydrochloride Extended-Release Tablets USP 750 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride Extended-Release Tablets USP 750 mg</intervention_name>
    <description>Metformin Hydrochloride Extended-Release Tablets 750 mg once a day</description>
    <arm_group_label>GLUCOPHAGE®XR</arm_group_label>
    <arm_group_label>Metformin Hydrochloride Extended-Release Tablets USP 750 mg</arm_group_label>
    <other_name>Test Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLUCOPHAGE®XR</intervention_name>
    <description>GLUCOPHAGE®XR 750 mg once a day</description>
    <arm_group_label>GLUCOPHAGE®XR</arm_group_label>
    <arm_group_label>Metformin Hydrochloride Extended-Release Tablets USP 750 mg</arm_group_label>
    <other_name>Reference product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged between 18 and 45 years (including both).

          2. Subjects' weight within normal range according to normal values for Body Mass Index
             (18.5 to 24.9 kg/m2) (including both) with minimum of 50 kg weight.

          3. Subjects with normal health as determined by personal medical history, clinical
             examination and laboratory examinations within clinically acceptable normal range.

          4. Subjects having clinically acceptable 12-lead electrocardiogram (ECG).

          5. Subjects having clinically acceptable chest X-Ray (PA view).

          6. Subjects having negative urine screen for drugs of abuse (including amphetamines,
             barbiturates, benzodiazepines, marijuana, cocaine, and morphine).

          7. Subjects having negative alcohol breathe test.

          8. Subjects willing to adhere to protocol requirements and to provide written informed
             consent.

          9. Subjects having negative Beta-hCG Pregnancy test (only for female subjects).

         10. For Female Subjects:

        1) Female of child bearing potential practicing an acceptable method of birth control for
        the duration of the study as judged by the investigator(s), such as condoms, foams,
        jellies, diaphragm, intrauterine device (IUD), or abstinence, or 2) Postmenopausal for at
        least 1 year, or if less than 1 year, then following acceptable contraceptive measures as
        mentioned above 3) Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
        hysterectomy has been performed on the subject).

        Exclusion Criteria:

          1. Hypersensitivity to Metformin or to any excipients or related class of drugs.

          2. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunological, dermatological, neurological or
             psychiatric disease or disorder.

          3. Any treatment which could bring about induction or inhibition of hepatic microsomal
             enzyme system within 1 month of the study starting

          4. History or Presence of significant alcoholism or drug abuse.

          5. History or presence of significant asthma, urticaria or other allergic reactions.

          6. History or presence of significant gastric and/or duodenal ulceration.

          7. History or presence of significant thyroid disease, adrenal dysfunction, organic
             intracranial lesion such as pituitary tumor.

          8. History or presence of cancer.

          9. History or presence of significant easy bruising or bleeding.

         10. History or presence of significant recent trauma.

         11. Subjects who have been on an abnormal diet (for whatever reason) during four weeks
             preceding the study.

         12. Difficulty with donating blood.

         13. Difficulty in swallowing solids like tablets or capsules.

         14. Use of any prescribed or OTC medication during last two weeks prior to dosing in
             period 01.

         15. Consumption of grapefruit juice, xanthine-containing products, tobacco containing
             products or alcohol within 48 hours prior to dosing.

         16. Major illness during 3 months before screening.

         17. Participation in a drug research study within past 3 months.

         18. Donation of blood from past 3 months before screening.

         19. Female subjects who are currently breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Hardik Dave, M.B.B.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veeda Clinical Research Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veeda Clinical Research Pvt. Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

